SIGNIFICANCE OF THIS STUDY
What is already known on this subject?
• A diverse group of monogenic conditions can present as very early onset IBD (VEOIBD).
• In the research setting, whole exome sequencing (WES) has facilitated the discovery of new VEOIBD genes and novel phenotypes of known conditions.
• Over 40 VEOIBD genes have been identified so far and are not routinely sequenced in patients with early onset and therapy-refractory disease.
What are the new findings?
• Targeted Gene Panel Screening (TGPS) revealed rare and unpredicted phenotypic variations.
• TGPS is a reliable genetic screening tool, leading to consistent coverage and variant detection across VEOIBD genes.
• In the diagnostic setting, WES performed with some limitations resulting in coverage deficiencies in several VEOIBD genes.
How might it impact on clinical practice in the foreseeable future?
• Comprehensive genetic screening in the diagnostic setting will reveal unexpected phenotypes, expand disease characterisation and open up new avenues for disease-specific treatments.
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MATERIAL AND METHODS

Patient cohort
Over a 12 month-period, 25 children were prospectively recruited for TGPS.
We included three patients with previously established genetic diagnoses (patient 5-7, Exons are illustrated in numerical order following their strand orientation (+/-). 
NGS analysis pipeline
The samples were aligned to the human reference genome GRCh37/Hg19
with Burrows-Wheeler Aligner (BWA) software 9 . The alignments were refined (base quality score recalibration, insertion-deletion realignment, duplicate removal) using the Genome Analysis Tool Kit (GATK) suite according to best practices suggested by the Broad Institute. Finally variants were called using UnifiedGenotyper (GATK) 10 .
We applied a 10-read cut-off to account for the increased risk of unreliable heterozygous variant calling in compound heterozygous or autosomal dominant disease models at low depth. We defined deficient exons as those containing one or more base pairs covered by less than ten reads.
Three in silico prediction tools were used for predicting the damaging effect of the reported mutations (SIFT 11 , PolyPhen-2 12 and MutationTaster 13 ). 
Ethical approval
Patients were informed and consented for NGS as part of the "PETIT Study". 
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Consequence of coverage instability on variant detection
As a surrogate for bp-position specific reliability and sensitivity we compared 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 We could show that screening patients for established monogenic VEOIBD diseases reveals rare phenotypic variations: Congenital tufting enteropathy (CTE) has been described as an epithelial disorder without evidence of intestinal inflammation 19 . As reported previously 20 , our results confirm that the presence of chronic inflammatory cells within the lamina propria does not exclude the diagnosis of CTE. Similarly, causative mutations in SKIV2L and TTC37, genes associated with tricho-hepato-enteric syndrome (THES), might lack key phenotypic features previously associated with the syndrome 14 21 suggesting that THES might be one of many possible phenotypes on the spectrum of variable gene penetrance involving the SKIV2L/TTC37 genes. WES studies have revealed novel 6 and unexpected genotypes 7 and
highlighted new pathways involved in the pathophysiology of VEOIBD.
Designed for optimal overall exome coverage 23 , specific considerations have to be made when WES is applied to investigate VEOIBD. Our study highlights that WES might have some limitations in the diagnostic setting due to coverage deficiencies in several VEOIBD genes. This is best exemplified by the coverage of IKBKG (NEMO Deficiency) and NCF1 (Chronic Granulomatous Disease): IKBKG and NCF1 baits have been frequently omitted in commercially available WES captures to avoid nonspecific alignment of reads to their pseudo gene loci leading to extensive coverage dropout 24 25 . As a consequence, WES failed to detect all five SNP's in NCF1 established by TGPS.
Another reported phenomenon potentially leading to false negative results, is the poor coverage of first exons 26 in WES data, which we also observed for VEOIBD genes. When considering patients for genetic screening, conventional single-gene analysis might still be feasible in selected patients with distinct phenotypes.
The nonspecific clinical profile of the majority of children however would favour NGS. In these cases sequential Sanger sequencing of potential candidate genes has been shown to far exceed the expenditure of time and expenses estimated for NGS analysis 7 .
Our data suggests that early comprehensive genetic screening can have a significant impact on patient management. Excluding or confirming known VEOIBD genotypes should therefore be considered early in the disease course in all cases of therapy-refractory VEOIBD.
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DISCLOSURE AND CONFLICT OF INTEREST
O ADA 12 1 - - - -1 1 - -8 - - - - - ADAM17 1 -1 - - - - - - -1 - -1 - - -3 - - - - - AICDA - -1 11 -12 - BTK -7 - -3 -8 - - - - -1 - -8 - -1 -3 -13 - -4 CD40LG - -8 - - CYBA 2 12 -1 -1 -1 -2 13 - 5 CYBB - -2 17 - -5 -1 17 -9 - -3 -2 - - -2 DCLRE1C* - - - 1 - - - - - - - - - - - DOCK8 8 4 - - - - - - - - - -8 - - - - - - - -6 - - - -6 - - - - - - - - - -1 -1 -2 -2 -7 EPCAM 9 5 - - - - -3 -6 - - FOXP3 4 15 -9 -1 8 - - - -2 -1 1 - - - GUCY2C - - - - - -3 - - - -5 - - - - - - - - - - - - -4 - - - HPS1 -3 -1 -2 6 -1 -1 -1 - - - -3 - -6 - -7 - - -1 13 HPS4 - - - - -4 - - - -7 - -4 -HPS6 13LRBA - - - - - - - - - - - - - -1 - - - - - -1 - - - - - - - - - -1 -5 - - - -5 - -14 -3 NCF1 6 -10 - 5 -9 - 6 -6 -8 - 3 - 3 - 3 - 2 NCF2 - - - - - - - -4 - - -1 - -9 - NCF4* 6 13 - -2 - - - - - -3 - PIK3R1* - - - - -14 - - - -6 - -2 - - - PLCG2 6 - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - RET 12 1 -2 - -9 5 -3 17 -1 - -1 3 - - - - - -5 10 - - - - - - SH2D1A 2 - -1 -6 SKIV2L - - - - - - - -2 - - - - - - - - -3 -4 - - - - - - -7 -2 - SLC37A4* - - - -1 -6 - - - -2 STXBP2 8 6 - - - - - -2 7 -1 - - -3 - - -2 - -1 -5 8 -9 - TTC37 -1 - - - -1 - - - - - - - - - - -1 - - - - -3 - - - - - - - -
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